All In Biotech

Drug Trial Radar · NCT07944508

A Phase 1 Study of MVB-101 Administered Intraprostatically in Patients With Localized Prostate Cancer Who Are Scheduled for Radical Prostatectomy

An Open-Label, Non-randomized, Multi-Center Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand Drug Conjugate MVB-101 Injected Into the Prostate of Patients With Localized Cancer of the Prostate Who Are Scheduled for Prostatectomy

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 14, 2026

Primary completion

Dec 2027

Study completion Mar 2028

Sponsor

Lead sponsor
MultiValent Biotherapies, Inc.Industry
Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1, open-label, non-randomized, multicenter study will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MVB-101 administered by direct intraprostatic injection in adults with previously untreated localized adenocarcinoma of the prostate who are scheduled to undergo radical prostatectomy. Participants will receive MVB-101 once weekly for 4 weeks. Part A will use an i3+3 dose-escalation design to evaluate dose levels of 1, 2, 4, and 8 mg and determine the maximum tolerated dose and recommended Phase 2 dose. Part B will use a Simon two-stage dose-expansion design at one or more selected dose levels to further characterize safety and preliminary efficacy. Participants will undergo safety, pharmacokinetic, multiparametric magnetic resonance imaging, pathological, prostate-specific antigen, and patient-reported outcome assessments.

Conditions

  • Localized Prostate Adenocarcinoma

Interventions

  • MVB-101Drug

    MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse eventsTime frame: From first dose through safety follow-up (approximately Day 50); treatment-related adverse events are followed through end of study (approximately Day 90)
  2. Dose-limiting toxicitiesTime frame: Day 1 through Day 29
  3. Maximum tolerated doseTime frame: Through completion of Part A dose escalation, up to 12 months
  4. Recommended Phase 2 doseTime frame: Through completion of dose escalation and applicable dose-expansion, up to 18 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Urology Centers of Alabama

    Homewood, Alabama · Recruiting

  • Urology San Antonio

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.